Pharmacogenomics: an opportunity for personalised psychotropic prescribing in adults with intellectual disabilities

被引：1

作者：

Perera, Bhathika ^{[1
]}

Steward, Charles ^{[2
]}

Courtenay, Ken ^{[1
]}

Andrews, Timothy ^{[3
]}

Shankar, Rohit ^{[4
,5
]}

机构：

[1] Barnet Enfield & Haringey Mental Hlth NHS Trust, London, England

[2] Congen Ltd, Cambridge, England

[3] Oxford Hlth NHS Fdn Trust, Oxford, England

[4] Univ Plymouth, Peninsula Sch Med, Plymouth, Devon, England

[5] Cornwall Partnership NHS Fdn Trust, Truro, England

来源：

BJPSYCH OPEN | 2022年 / 8卷 / 05期

关键词：

Intellectual disabilities; genetics; polypharmacy; psychotropics; discrimination;

D O I：

10.1192/bjo.2022.554

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

There is growing evidence for the use of pharmacogenomics in psychotropic prescribing. People with intellectual disabilities are disproportionately prescribed psychotropics and are at risk of polypharmacy. There is an urgent need for safeguards to prevent psychotropic overprescribing but it is equally crucial that this population is not left behind in such exciting initiatives. Understanding how genetic variations affect medications is a step towards personalised medicine. This may improve personalised prescribing for people with intellectual disabilities, especially given the high rate of psychiatric and behavioural problems in this population. Our editorial explores opportunities and challenges that pharmacogenomics offers for the challenges of polypharmacy and overprescribing of psychotropics in people with intellectual disabilities.

引用

页数：3

共 50 条

[31] Psychotropic prescribing practices in adults with intellectual disability and autism spectrum disorder in Richmond Neurodevelpmental Services
Dissanayake, Anushka
Davey, Nicholas
Patel, Rupal
[J]. BJPSYCH OPEN, 2021, 7 : S76 - S76
[32] Impact of Pharmacogenomics on Pediatric Psychotropic Medication Prescribing in an Ambulatory Care Setting
Tonti, Erica
Lee, Yee Ming
Gruenke, Nathan
Ferren, Janie
Stutzman, Danielle L.
[J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2024, 34 (01) : 52 - 60
[33] Psychotropic and side effects of individuals with intellectual and developmental disabilities
McLaren, Jennifer
[J]. JOURNAL OF APPLIED RESEARCH IN INTELLECTUAL DISABILITIES, 2021, 34 (05) : 1328 - 1328
[34] Psychotropic Use Among Youths With Intellectual and Developmental Disabilities
McLaren, Jennifer L.
Lichtenstein, Jonathan D.
Metcalfe, Justin D.
Charlot, Lauren R.
Drake, Robert E.
Beasley, Joan B.
[J]. PSYCHIATRIC SERVICES, 2021, 72 (09) : 988 - 997
[35] Ethical issues of psychotropic medication for people with intellectual disabilities
Raghavan, Raghu
Patel, Pradip
[J]. ADVANCES IN MENTAL HEALTH AND INTELLECTUAL DISABILITIES, 2010, 4 (03) : 34 - 38
[36] Symposium: Psychotropic Medication Use in People With Intellectual Disabilities
Courtenay, Ken
[J]. JOURNAL OF MENTAL HEALTH RESEARCH IN INTELLECTUAL DISABILITIES, 2017, 10 : 192 - 192
[37] National health surveillance of adults with disabilities, adults with intellectual and developmental disabilities, and adults with no disabilities
Havercamp, Susan M.
Scott, Haleigh M.
[J]. DISABILITY AND HEALTH JOURNAL, 2015, 8 (02) : 165 - 172
[38] Autism in adults with intellectual disabilities
Sappok, T.
Bergmann, T.
Kaiser, H.
Diefenbacher, A.
[J]. NERVENARZT, 2010, 81 (11): : 1333 - +
[39] Aging in adults with intellectual disabilities
Burt, DB
Primeaux-Hart, S
Loveland, KA
Cleveland, LA
Lewis, KR
Lesser, J
Pearson, PL
[J]. AMERICAN JOURNAL ON MENTAL RETARDATION, 2005, 110 (04): : 268 - 284
[40] Interviewing adults with intellectual disabilities
Gudjonsson, Gisli H.
Joyce, Theresa
[J]. ADVANCES IN MENTAL HEALTH AND INTELLECTUAL DISABILITIES, 2011, 5 (02) : 16 - 21

← 1 2 3 4 5 →